Skip Navigation

Japanese Journal of Clinical Oncology 2005 35(10):607-611; doi:10.1093/jjco/hyi165
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (2)
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Metindir, J.
Right arrow Articles by Bilir, G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Metindir, J.
Right arrow Articles by Bilir, G.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?


© 2005 Foundation for Promotion of Cancer Research

Ovarian Cyst Formation in Patients Using Tamoxifen for Breast Cancer

Jale Metindir1, Sabahattin Aslan2 and Gülay Bilir3

1 Department of Obstetrics and Gynecology, 2 Department of Surgery and 3 Department of Pathology, Ankara Oncology Hospital, Ankara, Turkey

For reprints and all correspondence: Jale Metindir, Ahmet Mithat Efendi Sokak No 58/11, 06550 Çankaya/Ankara, Turkey. E-mail: jmetindir{at}ttnet.net.tr

Received July 7, 2005; accepted August 10, 2005

Objective: The purpose of this study was to evaluate patient-related parameters that determine ovarian cyst formation in women using tamoxifen for breast cancer.

Methods: A retrospective review of tamoxifen-treated women with breast cancer who were followed up in the outpatient clinic at Ankara Oncology Hospital between January 2002 and December 2004 was performed. Tamoxifen doses and duration, post-treatment menstrual function, adjuvant therapy, ultrasonographic and hormonal [follicle-stimulating hormone and serum estradiol (E2)] data, details of gynecologic surgical procedure and histopathology were recorded.

Results: Twenty-nine of 150 tamoxifen-treated patients (19.3%) had ovarian cysts. Cysts were detected in 28 of 57 pre-menopausal women (49.1%) and 1 of 93 post-menopausal women (1.1%). Patients with ovarian cysts had higher serum E2 levels compared with patients without cysts (24 versus 345 pg/ml; P < 0.001). Patients with ovarian cysts had <1 year amenorrhoea duration (P < 0.001) compared with the patients without cysts. Adjuvant standard chemotherapy did not have relationship between the development of ovarian cysts. Multivariant analysis showed that cyst development is related to high E2 levels (P < 0.05).

Conclusions: Patients still having a menstrual cycle during tamoxifen had high risk (58.33%) of developing ovarian cysts. We have described an association between pre-menopausal patients using tamoxifen with high E2 level and ovarian cyst enlargement.

Key Words: tamoxifen • ovarian cysts • breast cancer • estradiol • follicle-stimulating hormone


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Cancer Prevention ResearchHome page
A. Y. Ting, B. F. Kimler, C. J. Fabian, and B. K. Petroff
Tamoxifen Prevents Premalignant Changes of Breast, but not Ovarian, Cancer in Rats at High Risk for Both Diseases
Cancer Prevention Research, December 1, 2008; 1(7): 546 - 553.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.